« Return to News | R&D Trends

Boehringer builds $42.5 million R&D facility

Thursday, August 25, 2011 10:57 AM

Boehringer Ingelheim Pharmaceuticals, broke ground on a new $42.5-million safety assessment building to be built over the next two years on its 294-acre campus in Ridgefield and Danbury, according to the Ridgefield Press.

The building, when completed in 2013, will provide more than 63,000 square feet of space for non-clinical safety studies in development as well as studies for research.

“The fact that Boehringer Ingelheim continues to invest in its campus and create jobs is great news for Connecticut,” said Connecticut Gov. Malloy. “This new facility expands the company’s research and development capacities, and reaffirms its reputation as an innovative and forward-looking company. Boehringer Ingelheim is a valued member of the Connecticut business community and a key partner in our collective efforts to strengthen the state’s bioscience industry.”

This new facility is a world class design combining state-of-the-art technology, compliance with current good manufacturing practice and process flexibility to handle production of the many different types of APIs discovered in research, Boehringer said.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.